Bortezomib in multiple myeloma

N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8. doi: 10.1056/NEJMc051943.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / economics*
  • Antineoplastic Agents / therapeutic use
  • Boronic Acids / economics*
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Cost-Benefit Analysis
  • Dexamethasone / economics*
  • Dexamethasone / therapeutic use
  • Drug Costs
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / economics
  • Multiple Myeloma / mortality
  • Pyrazines / economics*
  • Pyrazines / therapeutic use
  • Recurrence
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Dexamethasone